News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,573 Results
Type
Article (1393)
Company Profile (1)
Press Release (2179)
Section
Business (1140)
Career Advice (22)
Deals (136)
Drug Delivery (3)
Drug Development (1350)
Employer Resources (6)
FDA (183)
Job Trends (391)
News (2197)
Policy (611)
Tag
Academia (74)
Accelerated approval (1)
Adcomms (2)
Alliances (288)
Alzheimer's disease (9)
Antibody-drug conjugate (ADC) (4)
Approvals (162)
Artificial intelligence (11)
Autoimmune disease (3)
Bankruptcy (2)
Best Places to Work (356)
Biotechnology (1)
Brain cancer (1)
Cancer (33)
Cardiovascular disease (4)
Career advice (16)
CAR-T (3)
CDC (17)
Cell therapy (10)
Clinical research (538)
Collaboration (18)
Compensation (2)
Complete response letters (3)
COVID-19 (816)
CRISPR (1)
C-suite (10)
Cystic fibrosis (6)
Data (28)
Depression (1)
Diagnostics (74)
Diversity, equity & inclusion (2)
Drug discovery (1)
Drug pricing (2)
Duchenne muscular dystrophy (4)
Earnings (323)
Editorial (12)
Employer branding (1)
Employer resources (5)
Events (379)
Executive appointments (13)
FDA (199)
Funding (16)
Gene editing (7)
Generative AI (3)
Gene therapy (14)
GLP-1 (19)
Government (344)
Guidances (1)
Healthcare (239)
IgA nephropathy (1)
Immunology and inflammation (4)
Immuno-oncology (1)
Infectious disease (844)
Influenza (16)
Intellectual property (1)
Interviews (1)
IPO (83)
IRA (1)
Job creations (41)
Job search strategy (15)
JPM (3)
Labor market (6)
Layoffs (21)
Leadership (1)
Legal (60)
Lung cancer (3)
Machine learning (1)
Manufacturing (15)
MASH (1)
Medical device (33)
Medtech (33)
Mergers & acquisitions (63)
Metabolic disorders (18)
Neurodegenerative disease (2)
Neuroscience (14)
NextGen: Class of 2026 (43)
Non-profit (15)
Now hiring (25)
Obesity (13)
Opinion (10)
Pain (1)
Parkinson's disease (1)
Patents (11)
Patient recruitment (3)
People (432)
Phase 1 (247)
Phase 2 (281)
Phase 3 (305)
Pipeline (52)
Policy (19)
Postmarket research (5)
Preclinical (93)
Prostate cancer (1)
Psychedelics (4)
Radiopharmaceuticals (2)
Rare diseases (26)
Real estate (39)
Recruiting (3)
Regulatory (336)
Research institute (79)
Resumes & cover letters (4)
RSV (23)
Series A (1)
Series B (2)
Sickle cell disease (3)
Startups (65)
Supply chain (1)
Tariffs (3)
The Weekly (15)
Vaccines (340)
Venture capital (4)
Weight loss (7)
Date
Last 7 days (6)
Last 30 days (28)
Last 365 days (258)
2026 (31)
2025 (255)
2024 (291)
2023 (287)
2022 (520)
2021 (751)
2020 (564)
2019 (131)
2018 (96)
2017 (87)
2016 (73)
2015 (58)
2014 (39)
2013 (95)
2012 (85)
2011 (86)
2010 (55)
Location
Africa (23)
Alabama (3)
Arizona (1)
Asia (197)
Australia (16)
California (67)
Canada (7)
China (3)
Colorado (2)
Connecticut (1)
Europe (413)
Florida (1)
Illinois (2)
Indiana (2)
Japan (2)
Maryland (7)
Massachusetts (128)
New Jersey (14)
New York (16)
North Carolina (2)
Northern California (45)
Ohio (2)
Pennsylvania (21)
South America (12)
Southern California (11)
Texas (13)
United States (255)
Utah (2)
Washington D.C. (3)
Washington State (1)
3,573 Results for "moderna inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.
January 30, 2026
·
1 min read
·
Annalee Armstrong
Business
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Vaccines
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg
Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.
January 23, 2026
·
2 min read
·
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
influenza
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine
The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.
December 18, 2025
·
1 min read
·
Dan Samorodnitsky
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with efficacy increasing to 67% in those positive for PD-L1.
October 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
February 3, 2026
·
5 min read
·
Nick Paul Taylor
Pipeline
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth
Amid an aggressive savings push, Moderna has cut three assets and taken on a loan to increase “flexibility.”
November 21, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
A key question for investors going forward will be whether Moderna’s other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.
October 23, 2025
·
3 min read
·
Tristan Manalac
COVID-19
Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
In a July 9 memo, the director of the FDA’s Center for Biologics Evaluation and Research contended there was not enough evidence that the benefits of Moderna’s COVID-19 vaccine Spikevax outweighed its risks in healthy children.
July 16, 2025
·
2 min read
·
Tristan Manalac
1 of 358
Next
